Piramal Pharma Advances Oral Solid Dose Capabilities


As a result of new production area, India site’s total production capacity rises from 3 to 4.5 billion doses

Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO) and part of Piramal Pharma Limited, has a new production block available at the company's drug product site in Pithampur, located in state of Madhya Pradesh, India.

The new production area, known as “V Block”, is capable of handling batch sizes of 150 to 600 kilograms (about 331 to 1,323 pounds), which boosts the site's capacity to produce oral solid dosage form drug product. With the addition of V Block, the Pithampur site's total production capacity increases from 3 billion doses to 4.5 billion doses. The area features aqueous and non-aqueous wet granulation (high shear, top spray and bottom spray); direct, mono, and bilayer compression; aqueous and non-aqueous coating; and bottle packaging technologies. Aggregation capabilities related to FDA e-pedigree and track-and-trace requirements are in the works for V Block, along with the addition of dry granulation capabilities (roller compaction).

"The launch of this new large-scale production block represents a significant expansion of our ability to supply oral solid dosage form drug product to customers around the world,” says Peter DeYoung, Piramal Pharma Solutions’ CEO. “This additional capacity further reiterates our commitment to being a patient-centric organization that's focused on helping clients reduce the burden of disease on patients."

Related Videos
© 2024 MJH Life Sciences

All rights reserved.